+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
Infectious Disease Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Infectious Disease Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888743
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The infectious disease therapeutics market faces pivotal change driven by technology innovation, shifting regulations, and evolving supply chain dynamics. Senior decision-makers now require actionable insights that enable strategic portfolio management, operational resilience, and effective delivery of patient-focused solutions across a complex healthcare landscape.

Market Snapshot: Growth Trajectory and Value Drivers

Interest in infectious disease therapeutics remains robust, with the market maintaining steady expansion and a diverse flow of investments into advanced biologics, vaccines, and targeted therapies. Adaptive clinical trial models increase flexibility and enable more agile reactions to emergent health threats. The increasing adoption of digital engagement tools supports the sector’s durability in the face of operational challenges. Decision-makers in this segment must monitor varying demand cycles, incorporate regulatory updates, and adjust to new payer expectations, ensuring both patient needs and business objectives are met.

Scope & Segmentation: Infectious Disease Therapeutics Market Overview

This report delivers a comprehensive evaluation of the infectious disease therapeutics market, structured to aid leadership across market entry, investment, and portfolio planning. Key segmentation areas include:

  • Therapeutic Classes: The analysis spans antibiotics (aminoglycosides, beta-lactams, fluoroquinolones, macrolides, tetracyclines), antifungals (azoles, echinocandins, polyenes), antivirals (integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, protease inhibitors), biologics (cytokines, monoclonal antibodies), and vaccine platforms (conjugate, inactivated, live attenuated, subunit), reflecting extensive diversity in disease management.
  • Routes of Administration: The sector evaluates inhalation, intravenous, oral, and topical administration, each affecting therapy uptake, adherence, and patient support requirements.
  • Clinical Indications: The report covers COVID-19, gastrointestinal, hepatitis, HIV/AIDS, respiratory tract, skin, and urinary tract infections, each contributing different clinical, regulatory, and public health considerations.
  • Distribution Channels: Hospital, retail, and online pharmacies form critical links in the supply chain, shaping fulfillment operations and connections with healthcare providers.
  • End Users: Clinics, hospitals, and homecare environments are analyzed for their demand forecasting, tailored deployment models, and evolving service needs.
  • Regional Coverage: Market dynamics are outlined across the Americas, Europe, Middle East & Africa, and Asia-Pacific to highlight varying regulatory frameworks, manufacturing landscapes, and local investment activity.
  • Technology Adoption: The use of digital health tools and real-world evidence platforms spans identification, patient enrollment, disease surveillance, and lifecycle management, improving execution in competitive markets.

Key Takeaways for Senior Decision-Makers

  • Innovation in biologics, vaccines, and targeted modalities means organizations must frequently recalibrate portfolio priorities to remain competitive as the landscape evolves.
  • Transitioning toward value-based contracting requires organizations to invest in high-quality, longitudinal evidence and foster alignment across clinical, commercial, and procurement functions.
  • Integration of digital infrastructure at all stages—from clinical research to patient-facing programs—accelerates development timelines and sharpens operational oversight.
  • Complexity at the segment level calls for differentiated approaches to channel partnerships and pricing, ensuring sustainable growth amid heterogeneous market needs.
  • Strengthened collaboration among developers, manufacturers, and service partners supports scalability and risk mitigation, particularly as patient needs become more specific.
  • Region-specific regulatory requirements, local manufacturing resources, and capital flows necessitate targeted market access and data strategies for success across geographies.

Tariff Impact: U.S. Trade Actions and Strategic Realignment

U.S. tariffs applied in 2025 led manufacturers to revisit sourcing and distribution frameworks. Immediate cost pressures resulted in enhanced supply chain visibility and a shift toward diversified or localized suppliers, with many agreements updated to strengthen risk management. Procurement strategies now give priority to continuity, lead times, and supplier health, rather than solely price, underlining the heightened need for end-to-end collaboration among commercial, supply, and regulatory teams. This approach empowers organizations to better withstand market volatility and ensure uninterrupted availability of therapeutics.

Methodology & Data Sources

Research findings are grounded in direct interviews with clinical and supply chain executives, peer-reviewed literature, regulatory filings, and clinical trial data. Scenario-based stress testing, multi-reviewer validation, and rigorous quality controls ensure reliability. All processes adhere to ethical standards and confidentiality requirements.

Why This Report Matters for Infectious Disease Therapeutics

  • Supports leadership in forecasting and responding to disruptive market forces with evidence-based portfolio and operational strategies tailored at the segment and regional levels.
  • Provides actionable guidance for teams building resilient, patient-focused portfolios amid fluctuating supply chain and regulatory environments.
  • Offers a clear framework to engage stakeholders, optimize procurement, and inform strategic investments aligned to payer and health system needs.

Conclusion

This report equips senior leaders to reinforce supply resilience, drive patient-centered innovation, and shape commercially sound infectious disease therapeutic portfolios. Coordinated action and agile decision-making will remain fundamental for long-term market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Infectious Disease Therapeutics Market, by Drug Class
8.1. Antibiotics
8.1.1. Aminoglycosides
8.1.2. Beta Lactams
8.1.3. Fluoroquinolones
8.1.4. Macrolides
8.1.5. Tetracyclines
8.2. Antifungals
8.2.1. Azoles
8.2.2. Echinocandins
8.2.3. Polyenes
8.3. Antivirals
8.3.1. Integrase Inhibitors
8.3.2. Neuraminidase Inhibitors
8.3.3. Nucleoside Analogues
8.3.4. Protease Inhibitors
8.4. Biologics
8.4.1. Cytokines
8.4.2. Monoclonal Antibodies
8.5. Vaccines
8.5.1. Conjugate
8.5.2. Inactivated
8.5.3. Live Attenuated
8.5.4. Subunit
9. Infectious Disease Therapeutics Market, by Route Of Administration
9.1. Inhalation
9.2. Intravenous
9.3. Oral
9.4. Topical
10. Infectious Disease Therapeutics Market, by Indication
10.1. COVID-19
10.2. Gastrointestinal Infections
10.3. Hepatitis
10.4. HIV/AIDS
10.5. Respiratory Infections
10.6. Skin Infections
10.7. Urinary Tract Infections
11. Infectious Disease Therapeutics Market, by End User
11.1. Clinics
11.2. Homecare
11.3. Hospitals
12. Infectious Disease Therapeutics Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Infectious Disease Therapeutics Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Infectious Disease Therapeutics Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Infectious Disease Therapeutics Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Infectious Disease Therapeutics Market
17. China Infectious Disease Therapeutics Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Alexion Pharmaceuticals, Inc.
18.7. Allergan PLC
18.8. Amgen Inc.
18.9. Astellas Pharma US, Inc.
18.10. AstraZeneca PLC
18.11. Bayer AG
18.12. BioCryst Pharmaceuticals, Inc.
18.13. Biogen Inc.
18.14. Boehringer Ingelheim GmbH
18.15. Bristol-Myers Squibb Company
18.16. Celgene Corporation
18.17. Chimerix, Inc.
18.18. Eli Lilly and Company
18.19. Gilead Sciences, Inc.
18.20. GlaxoSmithKline PLC
18.21. Johnson & Johnson Services, Inc.
18.22. Merck & Co., Inc.
18.23. Mitsubishi Chemical Group Corporation
18.24. Mylan N.V.
18.25. Novartis AG
18.26. Novo Nordisk A/S
18.27. Pfizer Inc.
18.28. Sanofi S.A.
18.29. Takeda Pharmaceutical Co. Ltd.
List of Figures
FIGURE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 180. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 184. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 201. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 202. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 203. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 204. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 205. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 206. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 225. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 226. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 227. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 228. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 229. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 231. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 235. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 236. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 237. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 238. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 239. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 240. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 242. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 258. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 259. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 260. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 261. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 262. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 264. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 265. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 267. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 268. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 269. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 270. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 271. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 272. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 273. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 275. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 277. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 278. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 279. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 280. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 281. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 282. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 283. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 284. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 286. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 288. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 299. U

Companies Mentioned

The key companies profiled in this Infectious Disease Therapeutics market report include:
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chimerix, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Chemical Group Corporation
  • Mylan N.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 132.59 Billion
Forecasted Market Value ( USD ) by 2032 $ 183.13 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Infectious Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Infectious Disease Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 140 Pages
  • Global
From
Infectious Disease Therapeutics - Global Strategic Business Report - Product Image

Infectious Disease Therapeutics - Global Strategic Business Report

  • Report
  • 385 Pages
  • Global
From
Infectious Disease Clinical Trials Global Market Report 2025 - Product Image

Infectious Disease Clinical Trials Global Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Infectious Disease Therapeutics Market Report and Forecast 2025-2034 - Product Image

Infectious Disease Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Infectious Disease Therapeutics Market Report 2025 - Product Image

Infectious Disease Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.